BIOMOLECULAR LIFE HOLDINGS, INC.
Close on Oct 19, 2026
- Market cap
- $67.51M
- P/E (TTM)
- –
- Dividend yield
- –
About Biomolecular Life
Pharmaceutical Preparations, SIC 2834
VG Life Sciences Inc. is a biopharmaceutical drug discovery and development company focused on two core research platforms: Targeted Peptide Technology and Metabolic Disruption Technology. Its primary pipeline candidate is VG1177, a computationally designed anti-inflammatory peptide evaluated in preclinical studies for the treatment of HIV/AIDS and autoimmune diseases. The company's secondary clinical-stage asset investigates a metabolic disruption therapy combining hydroxychloroquine with sorafenib to treat drug-resistant solid tumor cancers, such as ovarian, breast, colon, lung, and pancreatic tumors. VG Life Sciences targets patients with advanced malignancies and autoimmune disorders, and it also holds a majority interest in a subsidiary exploring non-pharmaceutical agricultural oil applications.
The company operates out of executive offices located in Santa Barbara, California. Its developmental operations encompass early-stage clinical and preclinical research conducted in collaboration with North American academic institutions and healthcare centers, including clinical trial sites in Texas and preclinical safety testing facilities in Montreal, Canada.
Summary of the business section of Biomolecular Life's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BIOMOLECULAR LIFE HOLDINGS, INC.
- Founded
- 2001
- Headquarters
- Miami, FL
- Address
- 888 Brickell Key Dr,, # 306, 33131
- Phone
- (805) 879-9000
- Website
- vglifesciences.com.we
- Employees
- 1, Dec 31, 2014
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- BIOM
- Exchange
- OTC
- IPO date
- Dec 7, 1999
- Shares outstanding
- 108M, Nov 17, 2015
- Public float
- $1.26M, Dec 31, 2014
- Filer category
- Smaller reporting company
- Stock splits
- 1-for-20000 reverse, Apr 16, 2026; 1-for-600 reverse, Nov 27, 2012
- SEC CIK
- 1091326
- EIN
- 33-0814123
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Biomolecular Life's leadership is listed in its proxy statement (Form DEF 14A).
Corporate history
Events identified from SEC filings